BroPair Spiromax

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

xinafoate сальметерол, flutikazon propionat

Available from:

Teva B.V.

ATC code:

R03AK06

INN (International Name):

salmeterol, fluticasone propionate

Therapeutic group:

Lijekovi za opstruktivne plućne bolesti dišnih putova,

Therapeutic area:

Astma

Therapeutic indications:

BroPair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Product summary:

Revision: 1

Authorization status:

odobren

Authorization date:

2021-03-26

Patient Information leaflet

                                40
B. UPUTA O LIJEKU
41
UPUTA O LIJEKU:
INFORMACIJE ZA BOLESNIKA
BROPAIR SPIROMAX 12,75 MIKROGRAMA/100 MIKROGRAMA PRAŠAK INHALATA
salmeterol/flutikazonpropionat
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili
medicinskoj sestri.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika, ljekarnika ili medicinsku sestru.
To uključuje i svaku moguću nuspojavu koja nije navedena u ovoj
uputi. Pogledajte dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je BroPair Spiromax
i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati BroPair Spiromax
3.
Kako primjenjivati BroPair Spiromax
4.
Moguće nuspojave
5.
Kako čuvati BroPair Spiromax
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE BROPAIR SPIROMAX I ZA ŠTO SE KORISTI
BroPair Spiromax sadrži 2 djelatne tvari: salmeterol i
flutikazonpropionat:
•
Salmeterol je dugodjelujući bronhodilatator. Bronhodilatatori pomažu
da dišni putovi u plućima ostanu
otvoreni. Tako zrak lakše ulazi i izlazi iz pluća. Učinci
salmeterola traju najmanje 12 sati.
•
Flutikazonpropionat je kortikosteroid koji smanjuje otečenost i
nadraženost u plućima.
BroPair Spiromax se koristi za liječenje astme u odraslih i
adolescenata u dobi od 12 godina i stariji.
BROPAIR SPIROMAX POMAŽE U SPRJEČAVANJU NASTUPA NEDOSTATKA ZRAKA I
PISKANJA PRI DISANJU.
NE SMIJETE
GA KORISTITI ZA UBLAŽAVANJE NAPADAJA ASTME.
AKO IMATE NAPADAJ ASTME, PRIMIJENITE (SPASONOSNI)
INHALATOR S BRZODJELUJUĆIM LIJEKOM ZA HITNO UBLAŽAVANJE SIMPTOMA,
KAO ŠTO JE SALBUTAMOL.
UVIJEK SA
SOBOM MORATE IMATI SVOJ SPASONOSNI INHALATOR S BRZODJELUJUĆIM LIJEKOM
ZA UBLAŽAVANJE SIMPTOMA.
2.
ŠTO MORATE ZNATI PRIJE NEGO POČNETE PRIMJENJIVATI BROPAIR S
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
BroPair Spiromax 12,75 mikrograma/100 mikrograma prašak inhalata
BroPair Spiromax 12,75 mikrograma/202 mikrograma prašak inhalata
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna isporučena doza (doza iz nastavka za usta) sadrži 12,75
mikrograma salmeterola (u obliku
salmeterolksinafoata) i 100 ili 202 mikrograma flutikazonpropionata.
Jedna odmjerna doza sadrži 14 mikrograma salmeterola (u obliku
salmeterolksinafoata) i 113 ili
232 mikrograma flutikazonpropionata.
Pomoćna(e) tvar(i) s poznatim učinkom:
Jedna isporučena doza sadrži približno 5,4 miligrama laktoze (u
obliku hidrata).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Prašak inhalata
Bijeli prašak.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
BroPair Spiromax je indiciran za redovito liječenje astme u odraslih
i adolescenata u dobi od 12 godina i
starijih u kojih bolest nije odgovarajuće kontrolirana inhalacijskim
kortikosteroidima i prema potrebi
primjenjivanim inhalacijskim kratkodjelujućim β
2
-agonistima,.
4.2.
DOZIRANJE I NAČIN PRIMJENE
Doziranje
Bolesnike je potrebno savjetovati da uzimaju BroPair Spiromax svaki
dan, čak i kad nema simptoma.
Ako se simptomi jave u razdoblju između doza, potrebno je primijeniti
inhalacijski kratkodjelujući
beta
2
-agonist za njihovo hitno ublažavanje.
Kod odabira jačine početne doze BroPair Spiromaxa (12,75/100
mikrograma srednje doze inhalacijskog
kortikosteroida [IKS] ili 12,75/202 mikrograma visoke doze IKS-a,
potrebno je razmotriti težinu bolesnikove
bolesti, prethodnu terapiju astme uključujući dozu IKS-a te
bolesnikovu trenutnu kontrolu simptoma astme.
Liječnik treba redovito pregledavati bolesnike tako da doza
salmeterol/flutikazonpropionata koju primaju
ostaje optimalna i mijenja se samo na liječnički savjet. Dozu treba
titrirati na najnižu dozu kojom se održava
učinkovita kontrola simptoma.
Potrebno je imati na umu da se isporučene doze za BroPair Spiromax
razlikuju od drugih lijekova na t
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-08-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-08-2021
Public Assessment Report Public Assessment Report Bulgarian 14-04-2021
Patient Information leaflet Patient Information leaflet Spanish 27-08-2021
Public Assessment Report Public Assessment Report Spanish 14-04-2021
Patient Information leaflet Patient Information leaflet Czech 27-08-2021
Public Assessment Report Public Assessment Report Czech 14-04-2021
Patient Information leaflet Patient Information leaflet Danish 27-08-2021
Public Assessment Report Public Assessment Report Danish 14-04-2021
Patient Information leaflet Patient Information leaflet German 27-08-2021
Public Assessment Report Public Assessment Report German 14-04-2021
Patient Information leaflet Patient Information leaflet Estonian 27-08-2021
Public Assessment Report Public Assessment Report Estonian 14-04-2021
Patient Information leaflet Patient Information leaflet Greek 27-08-2021
Public Assessment Report Public Assessment Report Greek 14-04-2021
Patient Information leaflet Patient Information leaflet English 27-08-2021
Public Assessment Report Public Assessment Report English 14-04-2021
Patient Information leaflet Patient Information leaflet French 27-08-2021
Public Assessment Report Public Assessment Report French 14-04-2021
Patient Information leaflet Patient Information leaflet Italian 27-08-2021
Public Assessment Report Public Assessment Report Italian 14-04-2021
Patient Information leaflet Patient Information leaflet Latvian 27-08-2021
Public Assessment Report Public Assessment Report Latvian 14-04-2021
Patient Information leaflet Patient Information leaflet Lithuanian 27-08-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-08-2021
Public Assessment Report Public Assessment Report Lithuanian 14-04-2021
Patient Information leaflet Patient Information leaflet Hungarian 27-08-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 27-08-2021
Public Assessment Report Public Assessment Report Hungarian 14-04-2021
Patient Information leaflet Patient Information leaflet Maltese 27-08-2021
Public Assessment Report Public Assessment Report Maltese 14-04-2021
Patient Information leaflet Patient Information leaflet Dutch 27-08-2021
Public Assessment Report Public Assessment Report Dutch 14-04-2021
Patient Information leaflet Patient Information leaflet Polish 27-08-2021
Public Assessment Report Public Assessment Report Polish 14-04-2021
Patient Information leaflet Patient Information leaflet Portuguese 27-08-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 27-08-2021
Public Assessment Report Public Assessment Report Portuguese 14-04-2021
Patient Information leaflet Patient Information leaflet Romanian 27-08-2021
Public Assessment Report Public Assessment Report Romanian 14-04-2021
Patient Information leaflet Patient Information leaflet Slovak 27-08-2021
Public Assessment Report Public Assessment Report Slovak 14-04-2021
Patient Information leaflet Patient Information leaflet Slovenian 27-08-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 27-08-2021
Public Assessment Report Public Assessment Report Slovenian 14-04-2021
Patient Information leaflet Patient Information leaflet Finnish 27-08-2021
Public Assessment Report Public Assessment Report Finnish 14-04-2021
Patient Information leaflet Patient Information leaflet Swedish 27-08-2021
Public Assessment Report Public Assessment Report Swedish 14-04-2021
Patient Information leaflet Patient Information leaflet Norwegian 27-08-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 27-08-2021
Patient Information leaflet Patient Information leaflet Icelandic 27-08-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 27-08-2021